• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性血小板增多症患者的JAK2V617F、CALR和MPL突变与骨髓组织学

JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.

作者信息

Pich Achille, Riera Ludovica, Francia di Celle Paola, Beggiato Eloise, Benevolo Giulia, Godio Laura

机构信息

Section of Pathology, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy,

Section of Pathology, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.

出版信息

Acta Haematol. 2018;140(4):234-239. doi: 10.1159/000493970. Epub 2018 Nov 7.

DOI:10.1159/000493970
PMID:30404086
Abstract

INTRODUCTION

Mutations in the JAK2, CALR, and MPL genes have been shown to have prognostic value in essential thrombocythaemia (ET), but no clear association with morphological changes has been reported so far. We investigated the possible correlation between gene mutations and histopathological features in bone marrow (BM) biopsies of patients with ET.

METHODS

Marrow cellularity, fibrosis, and the number of total and dysmorphic megakaryocytes and clusters of megakaryocytes were compared to gene mutations in 90 cases of ET at diagnosis.

RESULTS

The JAK2V617F mutation was found in 58.9%, CALR in 28.9%, and MPL in 4.4% of the cases, and 7.8% were triple-negative. JAK2V617F-mutated ET showed a high BM cellularity, the lowest number of clusters of megakaryocytes and the highest number of dysmorphic megakaryocytes; CALR-mutated ET showed a reduced BM cellularity, many clusters of large megakaryocytes, and very few dysmorphic megakaryocytes; MPL-mutated ET showed the lowest BM cellularity, the highest number of clustered and large megakaryocytes, and the lowest number of dysmorphic megakaryocytes. Triple-negative ET cases had the highest BM cellularity.

CONCLUSIONS

Distinct morphological patterns were associated with gene mutations in ET, supporting the classification of ET into different subtypes.

摘要

引言

已证实JAK2、CALR和MPL基因的突变在原发性血小板增多症(ET)中具有预后价值,但迄今为止尚未报道其与形态学改变有明确关联。我们研究了ET患者骨髓活检中基因突变与组织病理学特征之间的可能相关性。

方法

对90例ET诊断病例的骨髓细胞密度、纤维化程度、总巨核细胞及异形巨核细胞数量和巨核细胞簇进行了与基因突变的比较。

结果

JAK2V617F突变在58.9%的病例中被发现,CALR突变在28.9%的病例中被发现,MPL突变在4.4%的病例中被发现,7.8%为三阴性。JAK2V617F突变的ET表现为高骨髓细胞密度、最低的巨核细胞簇数量和最高的异形巨核细胞数量;CALR突变的ET表现为骨髓细胞密度降低、许多大巨核细胞簇和极少的异形巨核细胞;MPL突变的ET表现为最低的骨髓细胞密度、最高的聚集和大巨核细胞数量以及最低的异形巨核细胞数量。三阴性ET病例具有最高的骨髓细胞密度。

结论

ET中不同的形态学模式与基因突变相关,支持将ET分为不同亚型。

相似文献

1
JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.原发性血小板增多症患者的JAK2V617F、CALR和MPL突变与骨髓组织学
Acta Haematol. 2018;140(4):234-239. doi: 10.1159/000493970. Epub 2018 Nov 7.
2
Essential thrombocythaemia with mutation in : clinicopathological correlation and comparison with 2V617F-mutated and mutated genotypes.伴有 JAK2 V617F 突变的原发性血小板增多症:临床病理相关性及与 JAK2 V617F 突变和突变基因型的比较
J Clin Pathol. 2018 Nov;71(11):975-980. doi: 10.1136/jclinpath-2018-205227. Epub 2018 Jun 22.
3
Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.越南原发性血小板增多症患者中JAK2V617F、CALR和MPL突变的临床及血液学相关性
Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2775-2780. doi: 10.31557/APJCP.2019.20.9.2775.
4
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.四种不同亚型骨髓增殖性肿瘤患者(原发性骨髓纤维化、原发性血小板增多症、真性红细胞增多症和无法分类的骨髓增殖性肿瘤)的CALR、JAK2和MPL突变谱
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.
5
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.骨髓增殖性疾病诊断标准的概念变迁以及骨髓增殖性肿瘤的分子病因学与分类:从1950年的达梅谢克到2005年的万琴克尔及以后
Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7.
6
Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.无Janus激酶2和MPL突变的原发性血小板增多症中钙网蛋白基因突变的临床表现:一项中国队列临床研究
Chin Med J (Engl). 2016 Aug 5;129(15):1778-83. doi: 10.4103/0366-6999.186641.
7
JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.中国汉族原发性血小板增多症患者的JAK2、MPL和CALR基因突变
Hematology. 2017 Apr;22(3):145-148. doi: 10.1080/10245332.2016.1252003. Epub 2016 Nov 22.
8
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients.CAL2 单克隆抗体是一种快速、灵敏的检测CALR 基因突变的方法,适用于原发性血小板增多症患者。
Ann Hematol. 2019 Oct;98(10):2339-2346. doi: 10.1007/s00277-019-03741-8. Epub 2019 Jun 27.
9
JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.真性红细胞增多症和主要血栓并发症中的JAK2 V617F、MPL及CALR突变:一项单机构回顾性分析
Pathol Oncol Res. 2015 Jul;21(3):751-8. doi: 10.1007/s12253-014-9885-4. Epub 2015 Jan 10.
10
CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.阿根廷BCR-ABL1阴性骨髓增殖性肿瘤患者中CALR、JAK2和MPL的突变状态
Hematology. 2018 May;23(4):208-211. doi: 10.1080/10245332.2017.1385891. Epub 2017 Oct 9.

引用本文的文献

1
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.低危原发性血小板增多症和特发性骨髓纤维化:治疗考虑和未来方向。
Ann Hematol. 2022 May;101(5):935-951. doi: 10.1007/s00277-022-04826-7. Epub 2022 Mar 28.
2
Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients.基于人工智能的巨核细胞形态指纹识别:一种评估骨髓增殖性肿瘤患者疾病的新工具。
Blood Adv. 2020 Jul 28;4(14):3284-3294. doi: 10.1182/bloodadvances.2020002230.